INTRODUCTION 47
48 Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), is currently endemic in the 49 world and represents an important public health problem every year. Globally, in 2017, more than 50 10 million new cases of TB were reported with an estimated 1.3 million deaths. Among 51 infectious diseases, TB is the leading cause of death from a single agent, surpassing the human 52 immunodeficiency virus (HIV) infection (1). Although TB affects mainly the lungs, 53 extrapulmonary forms can appear as an initial manifestation in approximately 25% of adults with 54 TB, of which the pleural space is the second site of involvement followed only by the lymph 55 nodes (2). In Brazil, a high burden TB country, PlTB is responsible for more than 40% of cases 56 among many clinical sites of extrapulmonary TB (3) and still imposes a challenging diagnosis 57 due to, mainly, its paucibacillary nature and the need of invasive producers (4). 58
Cellular immune response (Th1 immunity) involving CD4 + T-lymphocytes, classically 59 studied and associated with the containment of Mtb in pulmonary parenchymal TB, is also 60 predominant in TB pleuritis, which is confirmed by the higher levels of interferon-gamma (IFN-61 γ) and other inflammatory cytokines (e.g., IL-12) in pleural fluid in comparison to peripheral 62 blood (2, 5-7). IFN-γ promotes cell differentiation, stimulates an increased phagocytic activity 63 and intermediate nitrogen and oxygen species production, which are bactericidal and participate 64 in resistance to Mtb infection (8, 9) . In addition, other T-cell effectors patterns are involved in 65
Mtb control in the pleural microenvironment, such as Th17, which express the retinoic acid-66 related orphan receptor gamma t (RORγt), and are characterized by secretion of large quantities 67 of IL-17 (also known as IL-17A), IL-21, and IL-22 (9, 10). Th17 cells induce the expression of 68 many pro-inflammatory factors, chemokines, ultimately involved in granulopoiesis and 69 recruitment of innate cells, mainly neutrophils, especially in the early stages of infection (11, 12) . 70
It is well described that patients at early stages of the PlTB (less than 2 weeks duration) or those 71 who present pleural effusion with high complexity (e.g., loculated pleural effusion, TB 72 empyema) are more likely to have a neutrophilic exudate (reviewed by 13), which may contribute 73 to injuries and decreases pleuro-pulmonary functions. 74
Since that the gold standard for the diagnosis of PlTB which is the detection of Mtb in the 75 sputum, pleural fluid or pleural biopsy has a discrete and variable yield, the histological 76 demonstration of caseating granuloma even in the absence of acid-fast bacilli can be sufficient for 77 anti-TB treatment (14, 15). Additionally, values > 40 IU/L of adenosine deaminase (ADA) in 78 pleural effusion, a purine-degrading enzyme, associated with a predominantly lymphocytic 79 exudate, and clinical suspicious of TB, altogether, indicates that the most likely diagnosis is 80 tuberculosis (16, 17). However, high pleural fluid ADA values can also be found in certain 81 conditions, such as adenocarcinoma, lymphoma, rheumatoid arthritis, and pleural empyema of 82 bacterial etiology, making the differential diagnosis very hard (18, 19) . 83
Considering the difficulty in the differential diagnosis already mentioned and the current 84 knowledge about the products of the immune response against Mtb in pleural space, the present 85 study aimed to identify biomarkers among Th1, Th2, and Th17 T-cells subsets and other 86 inflammatory mediators in peripheral blood and pleural fluid which could present high potential 87 were defined by the patient history reviewed, followed by a detailed physical examination, and at 103 least one diagnostic criteria: i) positive results in the microbiological and/or histopathological following the manufacturer's instruction. The range of these assays was 31.3-20,000 pg/mL for 143 IP-10 and 15.6-1,000 pg/mL for TGF-β. Readings greater than the upper limit were set at 20,000 144 (IP-10) or 1,000 (TGF-β) pg/mL for the purpose of analysis. Table 1 . We observed a significant difference 170 between the age distributions between the groups, which presented medians corresponding to 65 171 years (IQR: 20) in the non-TB group, and 41 years (IQR: 14) in the PlTB group (p < 0.0001). 172
Smoking and alcoholic habits among participants did not show statistical differences. Similarly, 173 symptoms presentation was not dissimilar among groups. Fourteen (82%) patients in the non-TB 174 group had one or more comorbidities, showing that this group had a significantly higher number 175 of patients with comorbidities than observed in the P1TB group, which had 4 individuals (18%) 176 with others diseases (p = 0.0217). The most prevalent comorbidity was hypertension, which was 177 reported in 6 (35%) non-TB patients and 2 (9%) P1TB patients. Among non-TB patients, 13 were 178 malignancies, 1 autoimmune disease (systemic lupus erythematosus), and 3 undefined pleural 179 effusion. 180 181 Figure 1A and H) . As shown in Figure 1B , TNF concentration also showed a 192 significant increase in the pleural fluid when compared to serum in PlTB patient (p = 0.0016). 193
When these cytokines were compared with discriminatory objectives between PlTB and 194 non-TB patients, we predominantly observed significant differences in pleural fluid. IL-6 and IL-195 10 levels presented the same behavior when serum and pleural fluid were compared in PlTB or 196 non-TB groups ( Figure 1G Classically, the Th1 response is the most studied in TB, being responsible both for the 280 containment of Mtb and for the tissue injury caused by the excessive response to the bacillus 281 (reviewed by 28). As expected, Th1-related cytokines IFN-γ and TNF, as well as the biomarker 282 IP-10, are increased in the pleural fluid of P1TB patients compared to blood (Figure 1) . Recently, 283 the dosage of IFN-γ in pleural effusion raised importance as an auxiliary method for the diagnosis 284 of PlTB, becoming an example of a test used for this purpose, since this cytokine is at high levels 285
during the active phase of the disease (23, 28). The IFN-γ-release assay (IGRA) has also been 286 highlighted in this context. The test evaluates the activity of T lymphocytes under stimulation of 287 Mtb ESAT-6 and CFP-10 antigens. However, as reviewed by Aggarwal and collaborators (2015) 288 there are many conflicting results regarding this diagnostic method of active tuberculosis, both in 289 pulmonary and pleural forms (29). Moreover, as recently delineated by our group, IGRA has a 290 poor meaning in PlTB (7), perhaps due to their paucibacillary nature or due to the enrichment of 291 inflammatory mediators in pleural space, without needing of an additional antigen-stimuli. TNF 292 is another important mediator in the response against Mtb and it is directly related to the 293 maintenance of the granuloma structure, maintaining the colonization of the bacillus and necrosis 294 area in a restricted manner (30). Other evidence shows that patients treated with an anti-TNF 295 antibody developed active tuberculosis after reactivation of latent infection (31). In addition, TNF 296 is important in the intracellular control of Mtb (Review by 25). Li et al. (2014) found a higher 297 diagnostic value in TNF measurements than that found in ADA values (22) . IP-10 is well studied 298 as a possible biomarker in TB and is directly associated with INF-γ since its production is mainly 299 induced by this cytokine. As revised by Porcel (32), IP-10 is not an essential biomarker for the 300 PlTB diagnosis but has been the subject of several studies in this context, based on its 301 participation in the immunopathogenesis of the disease and their correlation with IFN-γ (7, 21). 302
Recently, the Th17 response also gained prominence in the immunopathology of 303 tuberculosis, especially in the early stages of infection (9, 10). Particularly in PlTB, Ye et al. 304 (2011) showed an increase of lymphocytes with Th17 profile in pleural fluid compared to blood. 305
Our results, presented here, show high concentrations of IL-6 and TGF-β in pleural fluid of PlTB 306 patients compared to serum (34). These two biomarkers are critical in the differentiation of Th17 307 cells (35). Therefore, although our study did not focus on the characterization of Th17 cells, it is 308 quite probable that the microenvironment, through the high concentration of IL-6, TGF-β, and the 309 low concentrations of IL-2 is favoring the differentiation of this T-lymphocytes effector 310 phenotype in the PLTB group. 311 IL-10 is a cytokine involved in the suppression of the immune response (36). In the case 312 of TB, it has been associated with suppression of dendritic cell activity, the formation of foamy 313 macrophages and defective formation of granuloma (37-39). The production of IL-10 is one of 314 the more classic mechanisms of suppression by T regulatory cells, however, this cytokine can be 315 produced by many other cells of the immune system, such as macrophages, B lymphocytes and 316
Th2 lymphocytes (40). Our study has shown higher concentrations of IL-10 in the pleural fluid of 317 patients with PlTB compared to serum, and in the same way in the NTB group. However, the 318 methodology used in this study was not able to identify which cells present in the pleural fluid 319 et al. (2013) showed an increased IL-10 production after stimulation of mononuclear cells in 321 pleural fluid and peripheral blood with Mtb antigens, and decrease of this cytokine after removal 322 of culture Treg cells provides evidence that Treg is also responsible for the production of IL-10 323 from the pleural cavity (41). 324
The cytokine pattern related to the Th2 effector phenotype was also evaluated. In the 325 methodology employed, but did not detect significant levels of IL-4. This finding confirms the 326 literature data that show little influence of this effector phenotype in cases of tuberculosis (2, 33), 327 although IL-4 concentrations in miliary TB have already been reported (5). 328
Another important finding in our study was the quantification of TGF-β in serum and 329 pleural fluid. This growth factor, secreted by monocytes, is a chemotactic agent for fibroblasts, 330 plays an important role in extracellular matrix remodeling (42). One of the possible contributions 331 of TGF-β to the pathophysiology of PlTB is its ability to induce fibrosis, as shown in the study by 332 Sasse et al (2003) , where animals infected with Mtb showed increased pleural thickening in 333 proportion to the increase in TGF-β (43). Seiscento et al (2007) also found elevated TGF-β 334 levels in serum and pleural fluid of PlTB patients, associating with the degree of pleural 335 thickening in these patients (44). Our findings, together with the evidence found in the literature, 336 reinforce the hypothesis that this mediator may be related to the development of pleural effusions 337 in TBP1 patients since TGF-β levels were found to be significantly higher in the pleural fluid of 338 these patients, compared to the results found in non-TB patients. Although the cited studies found 339 a significant increase of TGF-β in pleural fluid and serum, the comparison group in the 340 experimental model of these studies was composed of patients with transudative pleural effusion. 341
Our work was able to detect the increase of TGF-β in the serum and pleural fluid of PlTB 342 patients, compared to blood and pleural fluid in patients with other causes of exudative effusion.
to aid in the differential diagnosis of PlTB. 345
In fact, the cytokines analyzed alone are not able to provide data of high specificity and 346 sensitivity, especially in comparison to exudative effusions. However, when analyzed together, 347 they can provide high diagnostic value (7, 22) . Therefore, in the present study, PCA was 348 performed in an attempt to establish a pattern of cytokines and mediators in blood and pleural 349 fluid capable of discriminating the PlTB and non-TB cases. Our results show that 9 cytokines and 350 biomarkers, measured in blood and pleural fluid, were reduced to two principal components 351 (Table 2) 
